KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2025)

Vir Biotechnology's Other Non-Current Liabilities history spans 8 years, with the latest figure at $34.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 41.79% year-over-year to $34.1 million; the TTM value through Dec 2025 reached $34.1 million, up 41.79%, while the annual FY2025 figure was $34.1 million, 41.79% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $34.1 million at Vir Biotechnology, roughly flat from $34.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $46.0 million in Q1 2021 and bottomed at $2.5 million in Q4 2021.
  • The 5-year median for Other Non-Current Liabilities is $24.2 million (2023), against an average of $22.7 million.
  • The largest YoY upside for Other Non-Current Liabilities was 1464.79% in 2021 against a maximum downside of 87.44% in 2021.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.5 million in 2021, then surged by 337.6% to $11.1 million in 2022, then skyrocketed by 133.56% to $26.0 million in 2023, then decreased by 7.36% to $24.0 million in 2024, then surged by 41.79% to $34.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Other Non-Current Liabilities are $34.1 million (Q4 2025), $34.2 million (Q3 2025), and $33.6 million (Q2 2025).